An international phase 1b/2 clinical trial, known as KROCUS, is opening new avenues in the treatment of non-small cell lung cancer (NSCLC) with KRAS G12C mutation, one of the most challenging subtypes in thoracic oncology.
The study evaluates an innovative combination of two targeted drugs: fulzerasib, a specific inhibitor of KRAS G12C, and cetuximab, an antibody that blocks the EGFR receptor. This strategy aims to simultaneously target the tumor and the resistance mechanisms that often limit the effectiveness of targeted therapies in this type of cancer.
Preliminary results have generated significant interest within the scientific community. The combination has achieved a response rate close to 80%, far exceeding the results observed with single-agent targeted therapies. In addition, a progression-free survival of approximately 12.5 months has been observed, along with notable activity even in patients with brain metastases.
One of the most relevant aspects of the study is its focus on first-line treatment, raising the possibility of offering effective alternatives without initially resorting to chemotherapy or immunotherapy in certain patients.
The KROCUS trial, which is multicenter and international in nature, is at the forefront of precision oncology, exploring new therapeutic combinations based on the molecular characteristics of the tumor. Among the participating researchers is oncologist Santiago Viteri, whose contribution reinforces the role of clinical research in advancing more personalized treatments.
These results position this combination as one of the most promising strategies in addressing lung cancer with KRAS G12C mutation and open the door to future studies in more advanced phases that could redefine the standard of care for this group of patients.
